|Title:||Erythropoietin modulates macrophages but not post-ischemic acute kidney injury in mice||Authors:||YU-HSIANG CHOU
|Keywords:||Acute kidney injury; Colony-stimulating factor 2 receptor β; Erythropoietin; Ischemia-reperfusion injury; Macrophage||Issue Date:||Jan-2019||Publisher:||ELSEVIER TAIWAN||Source:||Journal of the Formosan Medical Association = Taiwan yi zhi||Abstract:||
Substantial progress was made in acute kidney injury (AKI) over the past 10 years, but no therapeutic interventions have been shown to prevent AKI or accelerate functional recovery after injury. A large number of preclinical studies supports the use of recombinant human erythropoietin (rHuEPO) to prevent AKI, but the clinical trial data are inconclusive. To address concerns about preclinical study design and reporting in AKI, we here presented our rigorous experiments on the use of rHuEPO in a mouse model simulating the most common post-ischemic AKI in patients.
|Appears in Collections:||醫學系|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.